olmesartan medoxomil has been researched along with Ventricular Dysfunction, Left in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujisawa, G; Iwazu, Y; Kimura, M; Kobayashi, E; Kobayashi, T; Kusano, E; Masuda, T; Murakami, T; Muto, S; Nonaka-Sarukawa, M; Sasaki, N; Shimada, K; Shinohara, M; Watanabe, Y | 1 |
| Ichinohasama, R; Kagaya, Y; Ninomiya, M; Shirato, K; Sugie, T; Takahashi, C; Takahashi, J; Takeda, M; Tezuka, F; Watanabe, J; Yahagi, H | 1 |
| Hori, M; Mano, T; Masuyama, T; Miwa, T; Nishikawa, N; Nishio, M; Ohtani, T; Sakata, Y; Yamamoto, K; Yoshida, J | 1 |
3 other study(ies) available for olmesartan medoxomil and Ventricular Dysfunction, Left
| Article | Year |
|---|---|
Heart angiotensin II-induced cardiomyocyte hypertrophy suppresses coronary angiogenesis and progresses diabetic cardiomyopathy.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Apoptosis; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Disease Models, Animal; Hypertrophy; Hypertrophy, Left Ventricular; Imidazoles; Male; Myocytes, Cardiac; Neovascularization, Physiologic; Olmesartan Medoxomil; Rats; Rats, Mutant Strains; Rats, Sprague-Dawley; Tetrazoles; Thrombospondin 1; Vascular Endothelial Growth Factor A; Ventricular Dysfunction, Left | 2012 |
Should increasing the dose or adding an AT1 receptor blocker follow a relatively low dose of ACE inhibitor initiated in acute myocardial infarction?
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Atrial Natriuretic Factor; Bradykinin; Collagen Type I; Collagen Type III; Drug Administration Schedule; Drug Therapy, Combination; Glyceraldehyde-3-Phosphate Dehydrogenases; Imidazoles; Male; Models, Animal; Myocardial Infarction; Myocardium; Norepinephrine; Olmesartan Medoxomil; Random Allocation; Rats; Rats, Wistar; RNA, Messenger; Tetrazoles; Thiazepines; Transforming Growth Factor beta; Ventricular Dysfunction, Left | 2003 |
AT1 receptor blocker added to ACE inhibitor provides benefits at advanced stage of hypertensive diastolic heart failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Calcium-Binding Proteins; Calcium-Transporting ATPases; Diastole; Disease Progression; Drug Therapy, Combination; Extracellular Matrix; Heart Failure; Heart Ventricles; Hemodynamics; Hypertension; Imidazoles; Inflammation; Male; Olmesartan Medoxomil; Rats; Rats, Inbred Dahl; Reactive Oxygen Species; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Tetrazoles; Thiazepines; Ventricular Dysfunction, Left | 2004 |